HMG CoA reductase inhibitors (statins) for kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Palmer, Suetonia C ^a   Navaneethan, Sankar D ^b   Craig, Jonathan C ^c,d   Perkovic, Vlado ^e   Johnson, David W ^f   Nigwekar, Sagar U ^g   Hegbrant, Jorgen ^h   Strippoli, Giovanni F M ^d,i,j,k,l  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Diaverum Renal Services Group   (Sweden)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^j UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^k Medical Scientific Office   (Sweden)

^l Diaverum Academy   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; AGED; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FATALITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART INFARCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASE; GRAFT REJECTION; KIDNEY TRANSPLANTATION; META ANALYSIS; MORTALITY;

CARDIOVASCULAR DISEASES; CHOLESTEROL; GRAFT REJECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KIDNEY TRANSPLANTATION; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84897442446     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005019.pub4     Document Type: Review

References (190)

1. Abedini S, Holme I, Fellstrom B, Jardine A, Cole E, Maes B, et al. Cerebrovascular events in renal transplant recipients. Transplantation 2009;87(1):112-7. [MEDLINE: 19136900]
2. Abedini S, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A, et al. Inflammation in renal transplantation. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(7):1246-54. [MEDLINE: 19541816]
3. Abedini S, Jardine A, Fellstrom B, Holdaas H. Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]. American Journal of Transplantation 2009;9(Suppl 2):207. [CENTRAL: CN-00763910]
4. Abedini S, Jardine A, Fellstrom B, Meinitzer A, Marz W, Bermann G, et al. Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F-FC149]. Journal of the American Society of Nephrology 2006;17(Abstracts):68A. [CENTRAL: CN-00689307]
5. Abedini S, Meinitzer A, Holme I, Marz W, Weihrauch G, Fellstrom B, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney International 2010;77(1):44-50. [MEDLINE: 19847152]
6. Fellstrom B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C, et al. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clinical Transplantation 2006;20(6):732-9. [MEDLINE: 17100723]
7. Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Grohagen-Riska C, et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation - experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):187A.
8. Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Effects of fluvastatin on graft losses and renal function in renal transplantation - experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):10A.
9. Fellstrom B, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Risk factors for graft loss or doubling of serum creatinine in renal transplantation - experience from the ALERT trial [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):185A.
10. Fellstrom B, Holdaas H, Jardine A, Holme I, Nyberg G, Gronhagen-Riska C, et al. Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):236. [CENTRAL: CN-00445309]
11. Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International 2004;66(4):1549-55. [MEDLINE: 15458450]
12. Fellstrom B, Holdaas H, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005;79(2):205-12. [MEDLINE: 15665769]
13. Fellstrom B, Holdass H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation - experience from the ALERT trial [abstract]. Transplantation 2004;78(2 Suppl):57. [CENTRAL: CN-00509185]
14. Fellstrom B, Jardine AG, Soveri I, Cole E, Gronhagen-Riska C, Neumayer HH, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005;79(9):1160-3. [MEDLINE: 15880062]
15. Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. American Journal of Transplantation 2005;5(8):1986-91. [MEDLINE: 15996249]
16. Fellstrom BC, Holdaas H, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]. American Journal of Transplantation 2004;4(Suppl 8):261. [CENTRAL: CN-00509187]
17. Holdaas H, Abedini S, Jardine A, Maes B, März W, Fellstrom B. Parathyroid hormone and phosphate - risk factors for post-transplant cardiovascular disease? [abstract no: TH-FC084]. Journal of the American Society of Nephrology 2006;17(Abstracts):19A. [CENTRAL: CN-00615900]
18. Holdaas H, Asberg A, Edvardsen C, Hartmann A. Statins endothelial function in renal transplant recipients - a randomised single centre study [abstract no: A4677]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):894A. [CENTRAL: CN-00776306]
19. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. American Journal of Transplantation 2005;5(12):2929-36. [MEDLINE: 16303007]
20. Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. Journal of Cardiovascular Risk 2001;8(2):63-71. [MEDLINE: 11324372]
21. Holdaas H, Fellstrom B, Jardin A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: M-PO50032]. Nephrology 2005;10(Suppl):A88. [CENTRAL: CN-00615876]
22. Holdaas H, Fellstrom B, Jardine A, Cole E, Maes B, Nyberg G, et al. Risk factors for late new-onset diabetes mellitus after renal transplantation [abstract no: 675]. American Journal of Transplantation 2005;5(Suppl 11):328. [CENTRAL: CN-00757934]
23. Holdaas H, Fellstrom B, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Lipid-lowering therapy should be started early in the post-transplant period [abstract no: F-PO569]. Journal of the American Society of Nephrology 2003;14(Nov):185A. [CENTRAL: CN-00550528]
24. Holdaas H, Fellstrom B, Jardine A, Cole E, Nyberg G, Gronhagen-Riska C, et al. Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: SO01]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v3. [CENTRAL: CN-00601991]
25. Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J, et al. No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]. Journal of the American Society of Nephrology 2004;15(Oct):881A. [CENTRAL: CN-00550529]
26. Holdaas H, Fellstrom B, Jardine A, Gimpelewicz C, Staffler B, Logan J, et al. Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA-PO1048]. Journal of the American Society of Nephrology 2004;15(Oct):527A. [CENTRAL: CN-00550531]
27. Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, Fauchald P, et al. Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]. American Journal of Transplantation 2003;3(Suppl 5):442. [CENTRAL: CN-00445757]
28. Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, et al. Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):237. [CENTRAL: CN-00445756]
29. Holdaas H, Fellstrom B, Jardine A, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]. Journal of the American Society of Nephrology 2005;16:72A.
30. Holdaas H, Fellstrom B, Jardine A, Nyberg G, Gronhagen-Riska C, Madsen S, et al. No detrimental effect on renal function during long-term use of fluvastatin [abstract]. Transplantation 2004;78(2 Suppl):327. [CN-00509236]
31. Holdaas H, Fellstrom B, Jardine AG, Cole E, Nyberg G, Gronhagen-Riska C, et al. Lipids as risk factors for cardiac events after renal transplantation - experience from the ALERT trial [abstract no: SU-PO590]. Journal of the American Society of Nephrology 2003;14(Nov):662A. [CENTRAL: CN-00550542]
32. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024-31. [MEDLINE: 12814712]
33. Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrology Dialysis Transplantation 2005;20(5):974-80. [MEDLINE: 15784644]
34. Holdaas H, Fellstrom B, Maes B, Cole E, Jardine A. Impact of hemoglobin levels on graft function, cardiac events and all-cause mortality after renal transplantation [abstract no: F-PO1502]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):443A. [CENTRAL: CN-00756929]
35. Holdaas H, Jardine A, Holme I, Brekke IB, Wheeler DC, Ostraat O, et al. A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy). 2000. [CENTRAL: CN-00527128]
36. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney International 2001; Vol. 60, issue 5:1990-7. [MEDLINE: 21561172]
37. Holme I, Fellstrom B, Jardine A, Holdaas H. Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. Atherosclerosis 2010;208(1):234-9. [MEDLINE: 19596331]
38. Jardine A, Weihrauch G, Maerz W, Fellstrom B, Bermann G, Holdaas H. Osteoprotegerin - a novel risk factor post-transplant cardiovascular disease [abstract no: TH-PO581]. Journal of the American Society of Nephrology 2006;17(Abstracts):231A. [CENTRAL: CN-00615825]
39. Jardine AG, Fellstrom B, Cole E, Logan J, Holdaas H. New targets for cardiovascular risk reduction in renal transplant recipients: post-hoc analyses of the ALERT study [abstract no: SU-PO991]. Journal of the American Society of Nephrology 2004;15(Oct):746A. [CENTRAL: CN-00550611]
40. Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. American Journal of Kidney Diseases 2005;46(3):529-36. [MEDLINE: 16129216]
41. Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. American Journal of Transplantation 2004;4(6):988-95. [MEDLINE: 15147434]
42. Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al. Pulse pressure and outcomes following renal transplantation [abstract no: SU-FC294]. Journal of the American Society of Nephrology 2003;14:64A. [CENTRAL: CN-00724902]
43. Jardine AG, Holdaas H, Fellstrom B, the ALERT Investigators. Adverse impact of steroids on outcome in the ALERT study [abstract]. American Journal of Transplantation 2004;4(Suppl 8):488. [CENTRAL: CN-00509253]
44. Norby G, Soveri I, Fellstrom B, Jardine A, Cole E, Maerz W, et al. C-Reactive protein (CRP) and interleukin-6 (IL-6) are associated with long-term renal and cardiac outcomes in renal transplant recipients [abstract no: SA-PO446]. Journal of the American Society of Nephrology 2007;18(Abstracts):438A-9A. [CENTRAL: CN-00716046]
45. Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S, et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis & Rheumatism 2009;60(4):1060-4. [MEDLINE: 19333947]
46. Oien CM, Reisaeter AV, Os I, Jardine A, Fellstrom B, Holdaas H. Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. Clinical Transplantation 2006;20(3):374-82. [MEDLINE: 16824157]
47. Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of Lipid Research 2007;48(9):2072-8. [MEDLINE: 17563401]
48. Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellstrom B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clinical Transplantation 2009;23(6):914-20. [MEDLINE: 19594771]
49. Soveri I, Holdaas H, Jardine A, Eriksson N, Fellstrom B. Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]. Transplantation 2008;86(2S):212. [CENTRAL: CN-00757239]
50. Soveri I, Holdaas H, Jardine A, Eriksson N, Fellstrom B. Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]. Transplantation 2008;86(2S):43. [CENTRAL: CN-00757241]
51. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994;68(1):57-62. [MEDLINE: 7991041]
52. Bill M, Paczek L, Gaciong Z, Gradowska L, Lao M, Wyzgal J, et al. Low dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]. Nephrology Dialysis Transplantation 1995;10(6):1061. [CENTRAL: CN-00261145]
53. Bill M, Paczek L, Wyzgal J, Baciong Z, Gradowska L, Lao M, Juskowa J, et al. Six-month treatment with low-dose lovastatin does not improve kidney allograft function. Polish Journal of Immunology 1995;20(4):417-9.
54. Paczek L, Bill M, Wyzgal J, Gaciong Z, Gradowska L, Juskowa J, et al. The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers. Polskie Archiwum Medycyny Wewnetznej 1997;97(2):144-56. [MEDLINE: 9312763]
55. Paczek L, Bill M. Wyzgal J, Gradowska L, Galazka Z, Gaciong Z. Non-immune factors in chronic rejection. Is there a role for hypolipemic drugs?. Annals of Transplantation 1997;2(2):65-9. [MEDLINE: 9869855]
56. Paczek L, Gradowska L, Bill M, Gaciong Z, Lao M, Juskowa J, et al. Treatment with low-dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]. Nephrology 1997;3(Suppl 1):S574. [CENTRAL: CN-00461456]
57. Castelao AM, Grino JM, Andres E, Gilvernet S, Seron D, Castineiras MJ, et al. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplantation Proceedings 1993;25(1 Pt 2):1043-6. [MEDLINE: 8442035]
58. Martinez-Castelao A, Grinyo JM, Gil-Vernet S, Seron D, Castineiras MJ, Ramos R, et al. Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. Transplantation Proceedings 2002;34(1):398-400. [MEDLINE: 11959343]
59. Celik A, Unsal A, Mutaf I, Habif S, Ok E, Bayindir O. Which dosage of simvastatin in renal transplant patients?. Nephron 2000;84(1):81-2. [MEDLINE: 10644914]
60. Cofan F, Gilabert R, Zambon D, Nunez I, Ros E, Cofan M, et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplantation Proceedings 2002;34(1):384-8. [MEDLINE: 11959338]
61. Cofan F, Zambon D, Laguna JC, Casals E, Ros E, Cofan M, et al. Pravastatin improves low-density lipoprotein oxidation in renal transplantation. Transplantation Proceedings 2002;34(2):389-91. [MEDLINE: 11959339]
62. Hausberg M, Barenbrock M, Stam F, Kosch M, Kisters K, Heidenreich S, et al. Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):677A. [CENTRAL: CN-00445668]
63. Hausberg M, Barenbrock M, Stam F, Kosch M, Kisters K, Spieker C, et al. HMG-CoA-reductase inhibitors improve brachial artery flow-mediated vasodilation in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A282. [CENTRAL: CN-00484274]
64. Hausberg M, Kosch M, Stam F, Heidenreich S, Kisters K, Rahn KH, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney International 2001;59(4):1473-9. [MEDLINE: 11260410]
65. Kosch M, Barenbrock M, Hausberg M. Sustained beneficial effect of a therapy with the HMG-Co-A-reductase inhibitor fluvastatin on endothelial function in renal transplant recipients. Nieren-und Hochdruckkrankheiten 2004;33(10):577-83. [EMBASE: 2004495206]
66. Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. American Journal of Kidney Diseases 2003;41(5):1088-96. [MEDLINE: 12722044]
67. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ. Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]. Transplantation 2000;69(8 Suppl):S225. [CENTRAL: CN-00446023]
68. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001;72(2):223-7. [MEDLINE: 11477342]
69. Katznelson S, Wilkinson AH, Danovitch GM, Wang XM, Chia D, Kobashigawa JA, et al. Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]. Journal of the American Society of Nephrology 1994;5(3):1017. [CENTRAL: CN-00601908]
70. Katznelson S, Wilkinson AH, Danovitch GM, Wang XM, Chia D, Ozawa M, et al. The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract]. 14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10-14; Chicago (USA). 1995.
71. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. Transplantation 1996;61(10):1469-74. [MEDLINE: 8633373]
72. Lepre F, Rigby R, Hawley C, Saltissi D, Brown A, Walsh Z. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clinical Transplantation 1999;13(6):520-5. [MEDLINE: 10617243]
73. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrology Dialysis Transplantation 1993;8(7):637-41. [MEDLINE: 8396749]
74. Martinez-Hernandez B, Persaud JW, Varghese Z, Moorhead JF. Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]. Journal of the American Society of Nephrology 1992;3(3):869. [CENTRAL: CN-00461259]
75. Melchor JL, Gracida C. Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplantation Proceedings 1998;30(5):2054. [MEDLINE: 9723390]
76. Raiola P, Manzo M, Saggese A. Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):693A. [CENTRAL: CN-00447330]
77. Renders L, Mayer-Kadner I, Koch C. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrology Dialysis Transplantation 2001;16(1):141-6. [MEDLINE: 11209008]
78. Renders L, Mayer-Kadner I, Koch C, Burkhardt K, Veelken R, Schmieder R, et al. Cerivastatin and atorvastatin: efficacy, safety and drug-interaction of the new HMG-COA reductase inhibitors in renal transplant patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):694A. [CENTRAL: CN-00447381]
79. Sahu K, Sharma R, Gupta A. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clinical Transplantation 2001;15(3):173-5. [MEDLINE: 11389707]
80. Sharma RK, Sahu KM, Gupta A, Gulati S, Agarwal DK, Kumar A, et al. Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A288. [CENTRAL: CN-00485837]
81. Garcia V, Bittar A, Keitel E, Neumann J, Saitovitch D, Santos A. Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441]. A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey). 2001. [CENTRAL: CN-00671773]
82. Garcia V, Bittar A, Keitel E, Neumann J, Saitovitch D, Santos A. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind, randomized placebo controlled study [abstract no: 1439]. A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey). 2001. [CENTRAL: CN-00615908]
83. Santos AF, Keitel E, Bittar A, Neumann J, Saitovich D, Seelig DC, et al. Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL). 2002. [CENTRAL: CN-00416585]
84. Santos AF, Keitel E, Bittar A, Neumann J, Saitovich D, Seelig DC, et al. Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind randomized placebo controlled study [abstract no:3367]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL). 2002. [CENTRAL: CN-00416586]
85. Santos AF, Keitel E, Bittar AE, Neumann J. Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double-blind, randomized, placebo-controlled study [abstract no: PO601]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy). 2000. [CENTRAL: CN-00465849]
86. Santos AF, Keitel E, Bittar AE, Neumann J, Fonseca N, Sporleder H, et al. Simvastatin effect on NK cells activity in vivo: a double-blind randomized, placebo-controlled study. Transplantation Proceedings 2002;34(7):2874-5. [MEDLINE: 12431639]
87. Santos AF, Keitel E, Bittar AE, Neumann J, Fuchs FD, Goldani JC, et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplantation Proceedings 2001;33(1-2):1194-5. [MEDLINE: 11267254]
88. Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, et al. Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial. Transplantation 2008;86(1):82-7. [MEDLINE: 18622282]
89. Sharif A, Ravindran V, Moore R, Baboolal K. The effects of rosuvastatin on 51CR-EDTA measured glomerular filtration rate and urinary albumin excretion in non-diabetic renal transplant recipients [abstract no: 1386]. Transplantation 2008;86(2S):466. [CENTRAL: CN-00766701]
90. Sharif A, Ravindran V, Moore R, Dunseath G, Luzio S, Owens D, et al. The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. American Journal of Transplantation 2009;9(6):1439-45. [MEDLINE: 19459810]
91. Sharif A, Ravindran V, Moore R, Dunseath G, Luzio S, Owens D, et al. The effects of rosuvastatin on insulin sensitivity and secretion in non-diabetic renal transplant recipients [abstract no: 611]. Transplantation 2008;86(2S):214. [CENTRAL: CN-00766702]
92. Sharif A, Ravindran V, Moore R, Luzio S, Dunseath G, Owens D, et al. Influence of rosuvastatin on attenuation of the metabolic syndrome in non-diabetic renal transplant recipients [abstract no: 60]. American Journal of Transplantation 2009;9(Suppl 2):208. [CENTRAL: CN-00775209]
93. Sharif A, Ravindran V, Moore R, Luzio S, Dunseath G, Owens D, et al. Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients. Journal of Diabetes 2009;1:A92-3. [EMBASE: 70212602]
94. Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clinical Transplantation 2003;17(4):385-90. [MEDLINE: 12868997]
95. Holdaas H, Jardine A, Holme I, SOLAR Study Group. The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A319. [CENTRAL: CN-00484378]
96. Holdaas H, Jardine A, Wheeler D. Fluvastatin (lescol) demonstrates significant lipid-lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212]. A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey). 2001. [CN-00445759]
97. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney International 2001;60(5):1990-7. [MEDLINE: 11703619]
98. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplantation Proceedings 2000;32(3):622-5. [MEDLINE: 10812143]
99. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-84. [MEDLINE: 15754269]
100. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):437a. [CENTRAL: CN-00444305]
101. Vergoulas G, Miserlis G, Gakis D, Imvrios G, Papagiannis A, Papanikolaou V, et al. Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A312. [CENTRAL: CN-00486302]
102. Bagdade JD, Shantharam VV, Sollek M, Albers JJ. Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients. Clinical Nephrology 1979;12(2):83-6. [MEDLINE: 230927]
103. Blechman-Krom I. An interventional trial in established chronic renal allograft rejection. www.clinicaltrials.gov/ct2/show/NCT00005010 (accessed 19 December 2013).
104. Blum CB, Rapamune US Study Group. Cholesterol and triglyceride levels in sirolimus-treated renal transplant recipients [abstract no: A3577]. Journal of the American Society of Nephrology 2000;11(Sept):680A. [CENTRAL: CN-00550429]
105. Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. American Journal of Nephrology 1999;19(3):411-5. [MEDLINE: 10393380]
106. Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, et al. Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrology Dialysis Transplantation 1997;12(10):2140-3. [MEDLINE: 9351079]
107. Cheng IKP, Li PWC, Janus ED, Tang CSO, Chan TM, Lo CY. Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) - a randomised prospective study [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:383. [CENTRAL: CN-00509131]
108. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney International 1982;22(1):42-7. [MEDLINE: 6750206]
109. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, Bojorquez-Ochoa A, Maya ER, Perez-Martinez MP. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatric Nephrology 2009;24(6):1205-10. [MEDLINE: 19238452]
110. Gonzalez-Molina M, Cabello M. Effect of diet, exercise and HMG-CoA reductase on hypercholesterolaemia in renal transplant patients [abstract]. Nephrology Dialysis Transplantation 1993;8(9):1040. [CENTRAL: CN-00260885]
111. Gonzalez-Molina M, Cabello M, Tinahones F, Burgos D, Lillo J, Soriguer F, et al. Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG-CoA reductase inhibition. Nefrologia 1996;16(4):359-64. [EMBASE: 1996302763]
112. Hilbrands LB, Demacker PN, Hoitsma AJ. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993;341(8847):765-6. [MEDLINE: 8095674]
113. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Journal of the American Society of Nephrology 1995;5(12):2073-81. [MEDLINE: 7579056]
114. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001;158(2):417-23. [MEDLINE: 11583721]
115. Imamura R, Ichimaru N, Moriyama T, Shi Y, Namba Y, Nonomura N, et al. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus. Clinical Transplantation 2005;19(5):616-21. [MEDLINE: 16146552]
116. Campistol JM, Legendre C, Castegneto M, Hartmann A, European US Global and Tri-Continental Study Groups. The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):880A. [CENTRAL: CN-00550752]
117. Kovarik JM, Hartmann S, Berthier S, Hubert M, Rordorf C, Somberg K. Statin therapy in renal transplant patients receiving everolimus: screening for clinical and pharmacokinetic drug interactions [abstract no:187]. American Journal of Transplantation 2002;2(Suppl 3):185. [CENTRAL: CN-00416055]
118. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990;49(1):95-100. [MEDLINE: 2105548]
119. Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplantation Proceedings 1996;28(6):3126-8. [MEDLINE: 8962211]
120. Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. American Journal of Kidney Diseases 1995;25(4):616-22. [MEDLINE: 7702060]
121. Lal SM, Petroski GF, Hewett JE, Van Stone JC, Ross G. Long term lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no:76P]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):946. [CENTRAL: CN-00484737]
122. Lal SM, Petroski GF, Hewett JE, Van Stone JC, Ross G. Three year follow up data on the lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no: 372]. Journal of the American Society of Nephrology 1995;6(3):1100. [CENTRAL: CN-00484738]
123. Lal SM, Van Stone J, Ross G Jr. Lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract]. Journal of the American Society of Nephrology 1992;3(3):866. [CENTRAL: CN-00461132]
124. Lal SM, Ross G. Lipid lowering effects of gemfibrozil and pravastatin with or without cholestyramine in diabetic renal transplant patients [abstract no: A3342]. Journal of the American Society of Nephrology 1996;7(9):1915. [CENTRAL: CN-00775367]
125. Lal SM, Habib S. Lipid lowering effects of niacin and lovastatin given alone or with cholestyramine in renal transplant patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):683A. [CENTRAL: CN-00446257]
126. Kaisar M, Armstrong K, Prins J, Marwick T, Johnson D, Hawley C, et al. The impact of aggressive cardiovascular risk modification on carotid intima media thickness and brachial artery reactivity in renal transplant recipients [abstract no: 132]. Nephrology 2008;13(Suppl 3):A134. [CENTRAL: CN-00766731]
127. Kaisar MO, Armstrong K, Hawley C, Campbell S, Mudge D, Johnson DW, et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrology 2009;10:29. [MEDLINE: 19821969]
128. Lopau K, Spindler K, Wanner C. Effects of pravastatin treatment on blood pressure regulation after renal transplantation. Kidney & Blood Pressure Research 2006;29(6):329-37. [MEDLINE: 17124431]
129. Markell MS, Sumrani N, Brown CD, Hong JH, Sommer BG, Friedman EA. Effect of hypercholesterolemia and lipid-lowering therapy on glomerular filtration rate in renal transplants [abstract no: 1808]. Journal of the American Society of Nephrology 1995;6(3):1103. [CENTRAL: CN-00484981]
130. Nart A, Uslu A, Bozkaya G, Aykas A, Dogan M, Karaca B. A prudent algorithm for hyperlipoproteinemia in renal transplant recipients. Transplantation Proceedings 2009;41(2):751-5. [MEDLINE: 19328972]
131. Nicholson PG, Raval DD, Behrens MT, Weir MR. A prospective cross over trial to compare the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients [abstract no: 76P]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):952. [CENTRAL: CN-00485241]
132. Ok E, Kursat S, Alev M, Tobu M, Tokat Y, Akcicek F, et al. Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. Nephron 1996;73(3):491-2. [MEDLINE: 8832618]
133. Olbricht C, Wanner C, Eisenhauer T, Christians U, Kliem V, O'Grady P, et al. Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]. Journal of the American Society of Nephrology 1995;6(3):1061. [CENTRAL: CN-00485312]
134. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clinical Pharmacology & Therapeutics 1997;62(3):311-21. [MEDLINE: 9333107]
135. Raiola P, Manzo M, Saggese A. Interaction of cyclosporine and fluvastatin with and without niacin in renal transplant patients with dyslipoproteinemia [abstract no: A3368]. Journal of the American Society of Nephrology 1996;7(9):1920. [CENTRAL: CN-00775265]
136. Renders L. Cardiovascular events in renal Transplant recipients with low LDL-cholesterol receiving tacrolimus in combination with the statin fluvastatin [CRANOC]. www.clinicaltrials.gov/ct2/show/NCT00223041 (accessed 19 December 2013).
137. Rigatto O, Rush D, Perry Y, Walker S, Bose R, Bolli P. Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation. Transplantation Proceedings 1997;29(6):2591-2. [MEDLINE: 9290755]
138. Rodriguez AP, De Bonis E, Gonzalez PJ, Torres A, Perez L, Dominguez ML, et al. Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega-3 fatty acids. Nefrologia 1997;17(1):49-54. [EMBASE: 1997130521]
139. Ruiz MC, Moreno JM, Ruiz N, Vargas F, Asensio C, Osuna A. Effect of statin treatment on oxidative stress and renal function in renal transplantation. Transplantation Proceedings 2006;38(8):2431-3. [MEDLINE: 17097958]
140. Turk S, Yildiz A, Tukek T, Akkaya V, Aras U, Turkmen A, et al. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. International Urology & Nephrology 2001;32(4):713-6. [MEDLINE: 11989571]
141. Vasquez EM, Sifontis N, Jacobssen V, Testa G, Sankary H, Benedetti E. Simvastatin for prevention of bone loss following renal transplantation [abstract no: P284]. Transplantation 2004;78(2 Suppl):293. [CENTRAL: CN-00509537]
142. White M, Hanes D, Wiland A, Klassen D, Hoen-Saric E, Schweitzer E, et al. Long-term treatment of hyperlipidemia in transplant recipients with pravastatin and gemfibrozil [abstract]. 15th Annual Meeting American Society of Transplant Physicians (ASTP);1996 May 10-14; Chicago (ILL). 1996.
143. Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006;82(6):771-8. [MEDLINE: 17006324]
144. NCT00565474. Evaluation of the effect of fluvastatin 40 μg (b.i.d.) in the prevention of the development of vasculopathy of the graft in de novo renal transplant patients transplant. www.clinicaltrials.gov/ct2/show/NCT00565474 (accessed 19 December 2013).
145. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology Dialysis Transplantation 1999;14(3):648-54. [MEDLINE: 10193814]
146. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. International Urology & Nephrology 1998;30(6):777-88. [MEDLINE: 10195874]
147. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288(23):2998-3007. [MEDLINE: 12479764]
148. Australia, New Zealand Dialysis, Transplant Registry (ANZDATA). The 33rd Annual Report 2010. http://www.anzdata.org.au/v1/report_2010.html (accessed 19 December 2013).
149. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78. [MEDLINE: 16214597]
150. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006;295(17):2046-56. [MEDLINE: 16670413]
151. Claesson K, Mayer AD, Squifflet JP, Grabensee B, Eigler FW, Behrend M, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplantation Proceedings 1998;30(4):1292-4. [MEDLINE: 9636524]
152. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;10(1):117-25. [MEDLINE: 8216498]
153. Cosio FG, Pesavento TE, Pelletier RP, Henry M, Ferguson RM, Kim S, et al. Patient survival after renal transplantation III: the effects of statins. American Journal of Kidney Diseases 2002;40(3):638-43. [MEDLINE: 12200817]
154. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-1681.
155. Del Castillo D, Cruzado JM, Manel Diaz J. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrology Dialysis Transplantation 2004;19(Suppl 3):iii67-71. [MEDLINE: 15192140]
156. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrology Dialysis Transplantation 2002;17(Suppl 4):26-8. [MEDLINE: 12091631]
157. Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney International 2004;66(4):1549-55. [MEDLINE: 15458450]
158. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74(8):1070-6. [MEDLINE: 12438948]
159. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67(7):1036-42. [MEDLINE: 10221490]
160. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
161. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57. [MEDLINE: 16345038]
162. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Journal of the American Society of Nephrology 1995;5(12):2073-81. [MEDLINE: 7579056]
163. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361(9374):2005-16. [MEDLINE: 12814710]
164. Isoniemi H, Nurminen M, Tikkanen, von Willebrand E, Krogerus L, Ahonen J, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994;57(1):68-72. [MEDLINE: 8291116]
165. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011;15:1419-27.
166. John GT, Dakshinamurthy DS, Jeyaseelan, Jacob CK. The effect of cyclosporine A on plasma lipids during the first year after transplantation. National Medical Journal of India 1999;12(1):14-7. [MEDLINE: 10326324]
167. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008;359(21):2195-207.
168. Kasiske BL, Guijarro C, Massy ZA, Wiederkher MR, Ma JZ. Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology 1996;7(1):158-65. [MEDLINE: 8808124]
169. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation 2004;4(Suppl 7):13-53. [MEDLINE: 15027968]
170. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:S1-155.
171. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996;34(1):51-61. [MEDLINE: 8880225]
172. Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrology Dialysis Transplantation 2004;19(9):2378-86. [MEDLINE: 15252155]
173. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. Journal of the American Society of Nephrology: JASN 2005;16(2):496-506. [PUBMED: 15615820]
174. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 1996;347(8994):102-3. [MEDLINE: 8538301]
175. Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 2001;72(6 Suppl):S13-5. [MEDLINE: 11585238]
176. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. American Journal of Health-System Pharmacy 2004;61(6):565-85. [MEDLINE: 15061429]
177. Mehra MR, Raval NY. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplantation Proceedings 2004;36(5):1539-41. [MEDLINE: 15251380]
178. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007784]
179. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. American Journal of Kidney Diseases 2002;39(2):S1-S266. [MEDLINE: 11904577]
180. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD004289.pub5]
181. Raine AE, Carter R, Mann JI, Morris PJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrology Dialysis Transplantation 1988;3(4):458-63. [MEDLINE: 3140134]
182. Satterthwaite R, Aswad S, Sunga V, Shidban H, Bogaard T, Asai P, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998;65(3):446-9. [MEDLINE: 9484771]
183. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58. [MEDLINE: 12686036]
184. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
185. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study. New England Journal of Medicine 1995;333(20):1301-7. [MEDLINE: 7566020]
186. USRDS. USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/2011/pdf/v2_ch04_11.pdf 2011. [MEDLINE: 14655174]
187. Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Van Buren CT, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989;48(1):37-43. [MEDLINE: 2665233]
188. Navaneethan SD, Perkovic V, Nigwekar SU, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005019.pub2]
189. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD005019.pub3]
190. Perkovic V, Craig JC, Masterson R, Webster A. HMG CoA reductase inhibitors (statins) for kidney transplant patients. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD005019]